Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

This year, BMS partnered to develop a PD-L1 and VEGF bispecific antibody and has acquired the rights to a new radiopharmaceutical asset.

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

Bristol-Myers Squibb (BMS) and Moffitt Cancer Center joined forces today as part of BMS’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a ...

Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...